The bicuspid aortic valve, a kind of heart disease that comes from parents, has been paid attention around the world. Thus, based on currently available data, we recommend careful patient selection within the heart team and shared decision-making with the informed patient. However, there is a major unmet need for more data, especially regarding long-term durability. However, data regarding the durability of the procedure are hitherto limited, and the procedure is associated with a higher complexity compared to aortic valve replacement.ĪVNeo using autologous pericardium in adult cardiac surgery is a promising technique providing several benefits. Potential benefits of this technique include excellent hemodynamic performances, minimal use of foreign material, low rates of permanent pacemaker implantation, and omission of oral anticoagulation. The aim of this article is to describe the technique of aortic valve neocuspidization using autologous pericardium (AVNeo, “OZAKI procedure”) in adult cardiac surgery, to analyze recent findings, and to discuss benefits and limitations of this technique. Long‐term follow‐up data are required for this novel approach to be widely adopted. The short‐ and midterm outcomes are comparable without the need for long‐term oral anticoagulation. Three studies reported their experience performing AV Neo via ministernotomy.ĪV Neo can be a suitable alternative to surgical AV replacement in selected patients. 66% of patients had a native tricuspid aortic valve (AV) and 31.37% of patients' native AV was bicuspid. 66.32% and 23.92% of patients had aortic stenosis and aortic regurgitation, respectively. The mean age was 67.36 and 54.23% were male. This technique has become an alternative to tissue and mechanical valve in selected patients as long‐term anticoagulation is not required and shows promising midterm results and durability.Ī comprehensive search was performed on the major database using the search terms “Ozaki technique” AND “Aortic Valve Neocuspidization” AND “AV Neocuspidization” AND “Autologous pericardium” AND “glutaraldehyde‐treated autologous pericardium.” Articles up to August 1st, 2021 were included in this study.Ī total of nine studies with a total of 1342 patients were included. Aortic valve neocuspidization (AV Neo) using glutaraldehyde‐treated autologous pericardium was first reported by Ozaki et al.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |